Premium
Use of liposome‐associated bupivacaine in a cancer pain syndrome
Author(s) -
Lafont N. D.,
Legros F. J.,
Boogaerts J. G.
Publication year - 1996
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.1996.tb12569.x
Subject(s) - medicine , bupivacaine , liposome , anesthesia , blockade , cancer pain , cancer , materials science , receptor , nanotechnology
Summary Bupivacaine. 0.25% encapsulated by multilamellar liposomes was administered epidurally to a patient suffering pain associated with lung cancer and the effect compared with a plain bupivacaine solution of the same concentration. Complete analgesia was produced for 4 h with the plain solution and 11 h with the liposomal formulation. No motor blockade or haemodynamic instability was observed with the liposome‐associated bupivacaine .